Bambusa Therapeutics has filed for an initial public offering to raise capital for clinical trials of its eczema drug, according to Bloomberg. The filing adds to a sparse 2026 biotech IPO calendar, where investors have been selective about backing clinical-stage dermatology programs.
Bambusa Therapeutics files for IPO to fund eczema drug trials
Bambusa Therapeutics filed for an initial public offering to fund clinical trials of its eczema treatment.
Why it matters: The filing tests investor appetite for biotech IPOs in a choppy 2026 market and funds the next stage of the company's dermatology pipeline.
Data as of Filing reported October 9, 2026. Bloomberg-only detail (article body blocked; pricing, share count and trial-stage details unverified); the filing itself is corroborated at headline level by Endpoints News, which also reports a Parkinson's cell-therapy biotech, Aspen, filing for an IPO alongside Bambusa.
Sources
- Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials · Bloomberg · 2026-10-09